Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
201.4 USD | -0.03% | -2.56% | -14.80% |
Jun. 28 | Argus Downgrades Charles River Laboratories International to Hold From Buy | MT |
Jun. 25 | Charles River Laboratories, Gates Institute Collaborate on Lentiviral Vector Manufacturing | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.80% | 10.38B | |
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+29.92% | 31.32B | |
-9.78% | 27.4B | |
+12.34% | 26.32B | |
+41.53% | 14.07B | |
+31.49% | 12.5B | |
-7.40% | 11.23B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Transcript : Charles River Laboratories International, Inc., Q1 2024 Earnings Call, May 09, 2024